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A B S T R A C T
Background
The main clinical intervention for mild to moderate hearing loss is the provision of hearing aids. These are routinely offered and fitted
to those who seek help for hearing difficulties. By amplifying and improving access to sounds, and speech sounds in particular, the aim
of hearing aid use is to reduce the negative consequences of hearing loss and improve participation in everyday life.
Objectives
To evaluate the effects of hearing aids for mild to moderate hearing loss in adults.
Search methods
The Cochrane ENT Information Specialist searched the ENT Trials Register; the Cochrane Register of Studies Online; MEDLINE;
PubMed; EMBASE; CINAHL;Web of Science; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials.
The date of the search was 23 March 2017.
Selection criteria
Randomised controlled trials (RCTs) of hearing aids compared to a passive or active control in adults with mild to moderate hearing
loss.
Data collection and analysis
We used the standard methodological procedures expected by Cochrane. The primary outcomes in this review were hearing-specific
health-related quality of life and the adverse effect pain. Secondary outcomes were health-related quality of life, listening ability and
the adverse effect noise-induced hearing loss. We used GRADE to assess the quality of the evidence for each outcome; this is indicated
in italics.
Main results
We included five RCTs involving 825 participants. The studies were carried out in the USA and Europe, and were published between
1987 and 2017. Risk of bias across the studies varied. Most had low risk for selection, reporting and attrition bias, and a high risk for
performance and detection bias because blinding was inadequate or absent.
All participants had mild to moderate hearing loss. The average age across all five studies was between 69 and 83 years. The duration
of the studies ranged between six weeks and six months.
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There was a large beneficial effect of hearing aids on hearing-specific health-related quality of life associated with participation in daily
life as measured using the Hearing Handicap Inventory for the Elderly (HHIE, scale range 1 to 100) compared to the unaided/placebo
condition (mean difference (MD) -26.47, 95% confidence interval (CI) -42.16 to -10.77; 722 participants; three studies) (moderate-
quality evidence).
There was a small beneficial effect of hearing aids on general health-related quality of life (standardised mean difference (SMD) -0.38,
95% CI -0.55 to -0.21; 568 participants; two studies) (moderate-quality evidence). There was a large beneficial effect of hearing aids on
listening ability (SMD -1.88, 95% CI -3.24 to -0.52; 534 participants; two studies) (moderate-quality evidence).
Adverse effects were measured in only one study (48 participants) and none were reported (very low-quality evidence).
Authors’ conclusions
The available evidence concurs that hearing aids are effective at improving hearing-specific health-related quality of life, general health-
related quality of life and listening ability in adults with mild to moderate hearing loss. The evidence is compatible with the widespread
provision of hearing aids as the first-line clinical management in those who seek help for hearing difficulties. Greater consistency is
needed in the choice of outcome measures used to assess benefits from hearing aids. Further placebo-controlled studies would increase
our confidence in the estimates of these effects and ascertain whether they vary according to age, gender, degree of hearing loss and
type of hearing aid.
P L A I N L A N G U A G E S U M M A R Y
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Review question
We reviewed the evidence on the effects that hearing aids have on everyday life in adults with mild to moderate hearing loss. We were
interested in (1) a person’s ability to take part in everyday situations, (2) general health-related quality of life, (3) ability to listen to
other people, and (4) harm, such as pain or over-exposure to noise.
Background
Hearing loss is very common and adults with hearing loss may be offered hearing aids. These devices increase the loudness, and may
improve the clarity, of sounds so that they are easier to hear. The main goal of hearing aids is to reduce the impact of hearing loss and to
improve a person’s ability to take part in everyday life. Although hearing aids are the most common technology for adults with hearing
loss and are in widespread use, it is not clear how beneficial they are.
Study characteristics
The evidence is up to date to 23 March 2017. We found five clinical studies involving 825 adults with mild to moderate hearing loss
who were randomly given either hearing aids, no hearing aids or placebo hearing aids. Studies involved older adults with the average
age within studies between 69 and 83 years. The duration of the studies was between six weeks and six months.
Key results
We found evidence in three studies that hearing aids have a large beneficial effect in improving the ability of adults with mild to
moderate hearing loss to take part in everyday situations. Hearing aids have a small beneficial effect in improving general health-related
quality of life, such as physical, social, emotional and mental well-being, and have a large effect in improving the ability to listen to
other people.
Only one study attempted to measure harms due to hearing aids. None were reported.
Quality of the evidence
We judged the evidence that hearing aids improve the ability to take part in everyday situations, improve general health-related quality
of life and improve listening ability to be of moderate quality. This means that while we are reasonably confident that the reported
benefits of hearing aids are real, there is a possibility that if further studies are conducted the size of the benefit might differ. We judged
the quality of evidence for harms to be very low, because this was only measured in one small study.
Conclusions
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We found that hearing aids improve the ability of adults with mild to moderate hearing loss to take part in everyday life, their general
quality of life and their ability to listen to other people. If an adult with mild to moderate hearing loss seeks help for their hearing
difficulties, hearing aids are an effective clinical option. It is important that future studies measure benefits consistently and report
benefits separately for different age groups, genders, levels of hearing loss and types of hearing aids.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Hearing aids versus no hearing aids for mild to moderate hearing loss in adults
Patient or population: adults with mild to moderate hearing loss
Setting: audiology services and clinics
Intervention: hearing aids
Comparison: no hearing aids (wait ing list) or placebo hearing aids
Outcomes
No. of participants
(studies)
Anticipated absolute effects (95% CI) Quality What happens∗
Without hearing aids With hearing aids Difference
Hearing-specif ic HRQoL
assessed with: HHIE (range
0 to 100)
Follow-up: range 6 to 16
weeks
No. of part icipants: 722 (3
RCTs)
The mean hearing-specif ic
HRQoL score was 39
- Mean 26 lower (42 to 11 lower) ⊕⊕⊕©
MODERATE 1,2,3,4
Lower score indicates better
hearing-specif ic HRQoL. The
mean dif ference corresponds to
a large ef fect size (SMD -1.38,
95% CI -2.02 to -0.75) favouring
hearing aids
Health-related QoL
assessed with: WHO-DAS II
(range 0 to 100) and the
SELF (range 54 to 216)
Follow-up: range 2 months
to 16 weeks
No. of part icipants: 568 (2
RCTs)
- - SMD 0.38 lower (0.55 lower to
0.21 lower)
⊕⊕⊕©
MODERATE 1,4
Lower score indicates better
HRQoL. The SMD corresponds
to a small ef fect size favouring
hearing aids, which is equivalent
to a 6-point decrease (9- to 3-
point decrease) on the 0 to 100
scale of the WHO-DAS II5.
Listening ability
assessed with: PHAP
(range 0 to 1) and APHAB
(range 0 to 100)
Follow-up: 6 weeks to 2
months
No. of part icipants: 534 (2
- - SMD 1.88 lower (3.24 lower to
0.52 lower)
⊕⊕⊕©
MODERATE 1,2,3,4
Lower score indicates improved
listening ability. The SMD cor-
responds to a large ef fect size
favouring hearing aids, which is
equivalent to a 29-point decrease
(50- to 8-point decrease) on the
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RCTs) 0 to 100 scale of the APHAB6.
Adverse ef fect - pain
No. of part icipants: 48
(1 RCT)
Adverse ef fects related to pain were measured in 1 study: none were reported ⊕©©©
VERY LOW7
There was too lit t le information
to est imate the risk of pain
Adverse ef fect - noise-in-
duced hearing loss
No. of part icipants: 48
(1 RCT)
Adverse ef fects related to noise-induced hearing loss were measured in 1 study:
none were reported
⊕©©©
VERY LOW7
There was too lit t le information
to est imate the risk of noise-in-
duced hearing loss
*The equivalent change in the intervention group (and its 95% conf idence interval) is based on the standard deviat ion in the comparison group f rom a representat ive study
(see footnotes for each outcome) and the relat ive ef fect of the intervent ion (and its 95% CI).
APHAB: Abbreviated Prof ile of Hearing Aid Benef it ; CI: conf idence interval; HHIE: Hearing Handicap Inventory for the Elderly; HRQoL: health-related quality of lif e; MD: mean
dif ference; PHAP: Prof ile of Hearing Aid Performance; RCT: randomised controlled trial; SELF: Self Evaluat ion of Life Funct ion; SMD: standardised mean dif ference; WHO-
DAS II: WHO Disability Assessment Schedule II
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Quality of evidence downgraded by one level because all studies have either a rat ing of unclear and/ or high risk bias in at
least one of these domains: select ion bias, performance and/ or detect ion bias.
2We considered downgrading for inconsistency due to observed stat ist ical heterogeneity but we did not apply this. The data
consistent ly showed large benef icial ef fects of using hearing aids for m ild to moderate hearing loss despite the apparent
dif f erences in study designs and populat ions. Our conf idence in the size of the ef fect is not af fected.
3We considered downgrading due to indirectness as some data were obtained af ter a short follow-up period (six weeks) but
we did not apply this. Large benef icial ef fects were observed regardless of durat ion of follow-up.
4We considered downgrading due to indirectness as some analyses included data f rom male military veterans but we did
not apply this. Ef fect sizes were consistent within each outcome despite dif f erences in study samples and designs (small
benef icial ef fect for HRQoL; large benef icial ef fect for hearing-specif ic HRQoL and listening ability).
5Equivalent change calculated assuming a standard deviat ion of 15.99 in WHO-DAS II scores in the no hearing aid group.
6Equivalent change calculated assuming a standard deviat ion of 15.30 in APHAB scores in the no hearing aid group.
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7Very serious imprecision as the sample size was very small. There was serious indirectness because only people with mild
to moderate Alzheimer’s disease were included in the study.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Hearing loss is the most prevalent sensory deficit (Mathers 2000),
and represents a major public health issue with substantial eco-
nomic and societal costs. Untreated, adult hearing loss results in
communication difficulties that can lead to social isolation and
withdrawal, depression and reduced quality of life (Davis 2007).
Hearing loss is also associated with an increased risk of dementia,
although currently the underlying mechanism is unknown (Lin
2011).
According to the World Health Organization, hearing loss is the
13th most common global disease burden and the third leading
cause of years lived with disability (YLD) (WHO 2008). Dis-
abling hearing loss is estimated to affect 360 million people glob-
ally (5.3% of the world’s population) (WHO 2012a). The preva-
lence of hearing loss increases with age (Akeroyd 2014), and given
the ageing society it is predicted that by 2030 adult-onset hearing
loss will be the seventh largest disease burden, above diabetes and
human immunodeficiency virus (HIV) (WHO 2008).
Epidemiological data suggest that the majority of cases of hearing
loss in adults are sensorineural in nature (92%) and occur bilat-
erally (94.8%) (Cruickshanks 1998). There are numerous defini-
tions of hearing loss across different countries and organisations
(Timmer 2015). In this review, hearing loss is defined according to
averaged pure-tone thresholds across combinations of frequencies
(0.5 kHz, 1.0 kHz, 2.0 kHz and 4.0 kHz), and grades of hearing
impairment are consistent with the World Health Organization
(Mathers 2000). The majority of hearing losses (92%) are those
that are defined asmild ormoderate (AoHL2015).Mild (or slight)
hearing loss is indicated as 26 to 40 dB hearing level (HL) and
described as the ability to hear and repeat words spoken in a nor-
mal voice at one metre. Moderate hearing loss is indicated as 41
to 60 dB HL and described as the ability to hear and repeat words
using a raised voice at one metre (Mathers 2000). In addition to a
loss of hearing sensitivity there may be additional sensory deficits
of temporal and spectral processing that contribute to speech per-
ception (Hopkins 2011), not necessarily captured by pure-tone
audiometry.
Description of the intervention
There are no effective medical or surgical treatments for mild to
moderate sensorineural hearing loss (Chisolm 2007), so the main
clinical intervention is the use of acoustic hearing aids (Kochkin
2009). It was estimated that in 2012, 11 million hearing aids were
soldworldwide (Kirkwood 2013).Hearing aids detect and amplify
sound, and deliver an amplified acoustic signal via air conduction
to the external auditory canal on the same side as the signals are
detected. Hearing aids are described according to where they are
worn (e.g. behind-the-ear, in-the-ear, in-the-canal, completely-in-
the-canal) or classified by their technology (i.e. analogue, digitally
programmable analogue or digital hearing aids) (Dillon 2012).
Hearing aids are typically fitted by healthcare professionals who
have been trained in audiology or the dispensing of hearing aids.
Hearing aid fittings can be unilateral or bilateral and they are
typically programmed according to the user’s pure-tone hearing
thresholds usinghearing aid prescription formulae (Mueller 2005).
Changes to the hearing aid programme may be made according
to subjective preference for sound quality, such as the perceived
loudness of sounds or the clarity of speech (McArdle 2005). Hear-
ing aid orientation that includes information on hearing aid use
and care, expectations and limitations is typically offered as usual
care (Boothroyd 2007; Reese 2005).
The use of hearing aids to amplify sounds does not necessarily re-
store hearing function. Frequency response characteristics of hear-
ing aids, distortions arising from peak clipping, poor clarity or
loudness of speech can all have an impact on successful listening
(Dillon 2012). As hearing aids amplify all sounds, not just speech
sounds, their use can lead to continued communication difficul-
ties, particularly in noisy backgrounds (Picou 2013). These and
other reasons can lead to non-use of hearing aids (McCormack
2013), with estimates of non-use varying from 3% (Bertoli 2009)
to 24% (Lupsakko 2005). Recent studies have shown non-use
at 10% (Aazh 2015) and 15.5% (Solheim 2017), consistent
with commercial surveys (4.7% to 7% (Hougaard 2011), 12.4%
(Kochkin 2010)). Additional interventions may be used to pro-
mote the use of hearing aids in people with hearing loss (Barker
2016).
How the intervention might work
The primary function of hearing aids is to amplify and improve the
audibility of sounds, and speech in particular.However, improving
the audibility of sounds or speech signals forms only one element
within the broader concept of rehabilitating a person with hearing
loss, where the overall aim is to reduce the negative consequences
of hearing loss and improve communication. In order to commu-
nicate effectively, an individual needs to access the acoustic infor-
mation (hearing, a passive process), employ attention and inten-
tion (listening, an active process), correctly interpret the acoustic
and linguistic information (comprehension, a unidirectional pro-
cess) and use and transmit this information effectively (communi-
cation, a bidirectional process) (Kiessling 2003). These processes
can be mapped onto the International Classification of Function-
ing, Disability and Health (ICF, WHO 2001), which provides a
theoretical framework upon which to measure the success of am-
plification using hearing aids.
Based on the ICF Core Set (Danermark 2013), the goal of ampli-
fication with hearing aids where there is mild to moderate hearing
loss is to reduce the auditory deficits associated with body func-
tions and structures, thereby reducing activity limitations and par-
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ticipation restrictions (Chisolm 2007; Kiessling 2003). Participa-
tion has been defined as involvement in a life situation, especially
engagement in a social domain, such as family relationships, com-
munity life, employment, education and recreation and leisure
(Danermark 2013; Resnik 2009; WHO 2002). Hearing-related
participation also has an emotional component, particularly feel-
ings of social isolation and loneliness (Ventry 1982).
Improvements in the ability of a patient with hearing aids to detect
and discriminate sounds and speech can be measured by acoustic
outcomes (e.g. free-field threshold and speech audiometry). The
consequences of these improvements in terms of activities and
participation can then be measured by patient-reported outcomes
such as self-report questionnaires, which can be defined as either
disease-specific (e.g. hearing) or generic (e.g. health-related quality
of life). Generic health-related quality of life measures generally
show limited benefit fromhearing aids as they lack sensitivity to the
consequences of hearing loss (Joore 2002; Joore 2003; Stark 2004).
There is, however, some evidence that the Health Utilities Index
Mark 3 (HUI3) is useful (Barton 2004; Davis 2007). Currently,
there is a lack of consensus on the optimal set of outcomemeasures
to use in hearing research (Granberg 2014).
Why it is important to do this review
Hearing aids are routinely offered and fitted for people with hear-
ing loss. It might seem obvious that such an intervention is bound
to be associated with an improvement in a patient’s ability to hear
and to communicate, but is this true? If there is an improvement
in a patient’s ability to hear and communicate, how big an im-
provement is it? There is little high-level evidence to answer these
questions and to inform discussions around the effectiveness of
hearing aids, their provision within a population and the approach
to be taken by those who might fund such provision.
There are no recent or ongoing systematic reviews that provide
the high-level evidence to inform clinical decision-making on this
important topic. A previous systematic review of the published
evidence included randomised controlled trials (RCTs) and non-
randomised trials published up to August 2004 that met specific
criteria. It sought to address a specific objective: to determine if
the use of hearing aids compared to the non-use of hearing aids
resulted in improvements in health-related quality of life for adults
with sensorineural hearing loss using disease-specific and generic
instruments (Chisolm 2007). The authors reported that there were
only two RCTs suitable for inclusion at that time, although only
one trial randomised the whole patient sample (Mulrow 1990),
therefore limiting the generalisability of the findings and the ro-
bustness of the conclusions. A more recent systematic review that
investigated hearing aid benefit in those with mild sensorineural
hearing loss included 10 studies, but none of these were RCTs
(Johnson 2016).
The present review does not compare the evidence for the bilat-
eral versus unilateral fitting of hearing aids, for which there is an
ongoing Cochrane Review (Browning 2017).
O B J E C T I V E S
To evaluate the effects of hearing aids for mild tomoderate hearing
loss in adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials and used the first treat-
ment period of cross-over trials (i.e. treated as a parallel-arm trial)
provided the study reporting permitted, where the unit of analysis
was the individual participant.
Types of participants
Adults (≥ 18 years old) who have mild to moderate hearing loss.
For inclusion, hearing loss of participants had to be either de-
scribed qualitatively as ’mild’ and/or ’moderate’, or the study group
had to be quantitatively defined as having an average pure-tone
threshold within the mild or moderate ranges of hearing loss as
defined by theWHO (mild: 26 to 40 dB HL inclusive; moderate:
41 to 60 dB HL inclusive). Here, an average pure-tone threshold
is defined as the mean of at least two octave frequencies up to and
including 4 kHz.
Types of interventions
Acoustic hearing aids, irrespective of where they are worn or the
type of technology (analogue or digital).
We excluded hearing aids or implantable devices whose primary
purpose is to deliver bone conduction sound or those that detect
and deliver sound via air conduction to the contralateral ear.
The comparisons of interest were hearing aids versus either a
passive control (no intervention, waiting list control; these were
pooled in the meta-analysis) or an active control that involved:
• information/education only, listening tactics and
communication training;
• assistive listening devices; or
• auditory training (we planned to analyse these second two
in separate meta-analyses).
We did not consider studies where the intervention was delivered
in a group setting.
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Types of outcome measures
The following outcomes were analysed in the review, but we did
not use them as a basis for including or excluding studies. We
analysed the data at the trial endpoint, with a planned subgroup
analysis to compare different trial endpoints. The ranked hierarchy
of instruments was derived from those reported in two systematic
reviews (Chisolm 2007 Table 4; Granberg 2014 Table 4).
Primary outcomes
• Hearing-specific health-related quality of life, where
participation was the key domain. This was measured using self-
report questionnaires. Where multiple questionnaires were used
in a study, we proposed a ranked hierarchy of instruments
whereby we identified the primary outcome based on the
following in order of importance:
◦ Hearing Handicap Inventory for the Elderly (HHIE;
Ventry 1982) or HHI for Adults (HHIA; Newman 1990), if the
HHIE was not used;
◦ Quantified Denver Scale of Communication (QDS;
Tuley 1990);
◦ Auditory Disability Preference - Visual Analogue Scale
(ADPI-VAS; Joore 2002); and
◦ any questionnaire not specified above that was relevant
to hearing-specific health-related quality of life.
For example, if both the HHIE and QDS were included in one
study, we would use only the HHIE in any meta-analysis.
• Adverse effect: pain. As reported by the patient as pain,
discomfort, tenderness or skin irritation, or reported as
occurrence of ear infection as a consequence of hearing aid
fitting.
Secondary outcomes
• Health-related quality of life. A ranked hierarchy of self-
report outcome measures was proposed in the following order:
◦ Health Utilities Index Mark 3 (HUI-3; Furlong 2001);
◦ EQ-5D (Rabin 2001);
◦ SF-36 (Ware 1992), or if not reported other short
forms of the SF-36;
◦ Glasgow Benefit Inventory (GBI; Robinson 1996);
◦ World Health Organization Disability Assessment
Schedule (WHO-DAS; WHO 2012b);
◦ Self-Evaluation of Life Function (SELF; Linn 1984);
and
◦ any questionnaire not specified above that was relevant
to health-related quality of life.
• Listening ability. A ranked hierarchy of self-report outcome
measures was proposed in the following order:
◦ Abbreviated Profile of Hearing Aid Benefit (APHAB;
Cox 1995);
◦ Speech, Spatial and Qualities of Hearing (SSQ;
Gatehouse 2004);
◦ Glasgow Hearing Aid Benefit Profile (GHABP,
residual disability subscale; Gatehouse 1999); and
◦ any questionnaire not specified above that was relevant
to self-report of listening ability.
• Adverse effect: noise-induced hearing loss, for example due
to over-amplification from inappropriate hearing aid fitting.
Search methods for identification of studies
The Cochrane ENT Information Specialist conducted systematic
searches for randomised controlled trials and controlled clinical
trials. There were no language, publication year or publication
status restrictions. The date of the search was 23 March 2017.
We contacted original authors for clarification and further data
when trial reports were unclear, and arranged translations of papers
where necessary.
Electronic searches
We searched the following databases from their inception for pub-
lished, unpublished and ongoing trials:
• the Cochrane Register of Studies Online (searched 23
March 2017);
• Epub Ahead of Print, In-Process & Other Non-Indexed
Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)
(1946 to 23 March 2017);
• Ovid Embase (1974 to 23 March 2017);
• EBSCO CINAHL (1982 to 23 March 2017);
• Ovid Cab (1910 to 23 March 2017);
• LILACS (searched 23 March 2017);
• KoreaMed (searched 23 March 2017);
• PakMediNet (searched 23 March 2017);
• Web of Knowledge, Web of Science (1945 to 23 March
2017);
• ClinicalTrials.gov, www.clinicaltrials.gov (searched via the
Cochrane Register of Studies 23 March 2017);
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP), www.who.int/ictrp (searched
23 March 2017);
• Google Scholar (searched 23 March 2017).
In searches prior to 2017 we also searched PubMed 1946 to Jan-
uary 2016 as a top-up toOvidMEDLINE and IndMed to January
2017.
The Information Specialist modelled subject strategies for
databases on the search strategy designed for CENTRAL. Where
appropriate, theywere combined with subject strategy adaptations
of the highly sensitive search strategy designed by Cochrane for
identifying randomised controlled trials and controlled clinical tri-
als (as described in theCochraneHandbook for Systematic Reviews of
Interventions Version 5.1.0, Box 6.4.b. (Handbook 2011). Search
strategies for major databases including CENTRAL are provided
in Appendix 1.
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Searching other resources
We scanned the reference lists of identified publications for addi-
tional trials and contacted trial authors where necessary. In addi-
tion, the Information Specialist searched Ovid MEDLINE to re-
trieve existing systematic reviews relevant to this systematic review
so that we could scan their reference lists for additional trials.
Data collection and analysis
Selection of studies
Material downloaded from electronic sources included details of
author, institution, journal of publication and abstract. Two of the
three screening authors (MF, DH and FB) independently screened
each study against the inclusion criteria to determine their eligi-
bility for inclusion in the review. Where the decision about any
one study was not unanimous among the screening authors or
there was insufficient information, we acquired the full article for
further inspection. Once the full articles were obtained, we de-
cided whether the studies met the review criteria, and where there
were disagreements we reached a final decision by discussion and
consensus.
We revised the inclusion criteria for participants part-way through
the review process. The revised definition for Types of participants
and the final decision about which studies to include were subject
to independent review by an external expert committee to ensure
that it was appropriate for the review question. The risk of revis-
ing the protocol was minimised, because this committee also in-
dependently evaluated the studies (shortlisted by the authors) and
agreed that they met the new inclusion criterion. See Differences
between protocol and review for details.
Data extraction and management
MF and PK independently extracted data from the articles. We
recorded the extracted data using the Covidence systematic review
software (Covidence 2017) on review-specific forms. We devel-
oped and assessed these for suitability through pilot testing prior
to independent data extraction. Where there were discrepancies in
the data extracted from either the main body or a table we made
a final decision by discussion. Where data were extracted from
graphs, we used the average of the two independent extractions.
Whenever discrepancies were detected, a third author was involved
to reconsider and resolve the differences.
Information extracted included: trial design, setting, methods of
randomisation and blinding, power, inclusion and exclusion crite-
ria, type of intervention and control, time since hearing aid fitting,
duration of follow-up, outcome measures and statistical tests.
For both the intervention and control groups, data extraction in-
cluded: baseline characteristics of participants (number, sex, age),
details of their hearing loss (mean, standard deviation, range), and
details of any attrition or exclusion. For the intervention group,
we extracted details of hearing aids (ear on which they were worn,
analogue or digital, in-the-ear or behind-the-ear, manufacturer,
unilateral or bilateral hearing aid fittings, and fitting procedures if
reported).
Outcome measure data included: group means and standard de-
viations at pre- and post-intervention and follow-up, number of
participants and results of statistical tests of between-group com-
parisons.
We contacted the authors of all included studies as further infor-
mation was required on all studies after inspection of the full arti-
cles. After independent data extraction by MF and PK, there were
no disagreements that could not be resolved through discussion.
Assessment of risk of bias in included studies
MF and PK independently assessed the risk of bias of the included
trials, with the following taken into consideration, as guided
by theCochrane Handbook for Systematic Reviews of Interventions
(Handbook 2011):
• sequence generation;
• allocation concealment;
• blinding of (i) participants and study personnel
(performance bias), and (ii) outcome assessment (detection bias);
• incomplete outcome data;
• selective outcome reporting; and
• other sources of bias.
We used the Cochrane ’Risk of bias’ tool in RevMan 5.3 (RevMan
2014), which involved describing each of these domains as re-
ported in the trial and then assigning a judgement about the risk
of bias on the outcomes measured as a result of each entry: ’low’,
’high’ or ’unclear’ risk of bias. Where there were disagreements
that could not be resolved, DH reviewed the paper and made a
final judgement.
Measures of treatment effect
We expressed continuous outcomes as the size of the difference in
treatment effect between an intervention group and a comparator
group at the trial endpoint in terms of either the mean difference
(MD), when the same outcome measures were used across stud-
ies, or the standardised mean difference (SMD), when different
outcome measures were used across studies. The calculation of the
effect size used the pooled standard deviation, and we reported the
95% confidence interval (CI) for eachMD or SMD. An effect size
less than 0 indicated that a larger treatment effect was observed in
the treatment group relative to the comparator group. We did not
extract any binary data.
Unit of analysis issues
The unit of analysis was the participant. We anticipated that par-
ticipant-level data would not generally be available and therefore
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reported suitable summary statistics that were provided in the ar-
ticles. As stated above, in the case of cross-over trials we only in-
cluded data from the first period.
Dealing with missing data
We contacted the corresponding authors of all the included studies
to obtain missing data, except McArdle 2005 because they used
imputation to account for missing data. We obtained participant-
level data from Humes 2017, but we received no data from the
other three studies, two of which no longer had the data available
(Melin 1987; Mulrow 1990).We either took data from tables pre-
sented in the published manuscripts or estimated data from pub-
lished figures, as described in theData extraction andmanagement
section. Where standard deviations were not reported or provided
by the authors, we estimated standard deviations in RevMan 5.3
(RevMan 2014) using available data, such as standard errors, 95%
confidence intervals, P values and t values. We reported the extent
of the missing data within studies. Data were not available for any
subgroups of interest.
Assessment of heterogeneity
We assessed heterogeneity among treatment effect sizes using
RevMan 5.3 (RevMan 2014), and we expressed this in terms of
the I2 statistic. We assessed the statistical significance (P = 0.10)
using a Chi2 test with K-1 degrees of freedom.We quantified het-
erogeneity in terms of the I2 statistic with low, medium and high
ranges of 0% to 40%, 41% to 60% and 61% to 100%, respec-
tively.
Assessment of reporting biases
We planned to assess publication bias by examining a funnel plot
of the size of treatment effects plotted against their variability.
However, there were insufficient studies to assess whether the plot
was symmetrical or to quantify the deviation from the expected
symmetrical pattern using the ’trim and fill’method (Duval 2000).
Data synthesis
We conducted random-effects meta-analyses of the MDs and
SMDs using RevMan 5.3 (RevMan 2014). We used random-ef-
fects models as we anticipated significant heterogeneity among
treatment effects across studies. For each meta-analysis, we re-
ported a summary effect size estimate in terms of theMDor SMD,
together with its 95%confidence interval.We calculated summary
effects using the inverse variance procedure.
To help with the interpretation of data, we estimated the ’equiva-
lent’ change on one of the more commonly used scales whenever
SMDs were used to summarise data from a few different patient-
reported outcome instruments. We multiplied the observed SMD
by the standard deviation of a representative study.
Subgroup analysis and investigation of heterogeneity
Wehad planned to use subgroup analyses to assess possible sources
of heterogeneity. While heterogeneity was identified (see Effects
of interventions), it was not possible to perform subgroup analyses
based on age, sex and degree of hearing loss as data on subgroups
were not available. Time between fitting and trial endpoint was
also identified as a possible source of heterogeneity, but a planned
subgroup analysis comparing trials with different endpoints (up to
three months, over three months to six months and six months or
more) was not possible due to the small number of included stud-
ies. We conducted a post-hoc subgroup analysis for the hearing-
specific health-related quality of life outcome due to the observed
pattern of effects across studies (see Effects of interventions) and
the differences in participant groups (e.g. military personnel com-
pared with community dwellers).
Sensitivity analysis
We had planned to perform sensitivity analyses to informally test
the robustness of assumptions from the data. The small number of
studies precluded sensitivity analyses to assess uncertainty about
aspects of the included studies, in terms of randomisation (ran-
dom/quasi-random), missing data (greater than 30% at the pri-
mary endpoint) and description of hearing loss (mild/moderate).
GRADE and ’Summary of findings’ table
Using the GRADE approach, two review authors (PK, DH) inde-
pendently rated the overall quality of evidence using the GDT tool
(http://www.guidelinedevelopment.org/) for the main compari-
son pairs listed in the Types of interventions section. MF and LYC
reviewed the ratings and resolved any queries and disagreements.
In addition, we also presented the data to a guideline panel that
consisted of clinical experts, methodologists and patient represen-
tatives and we took their comments into account to reach the final
ratings. The quality of evidence reflects the extent to which we are
confident that an estimate of effect is close to its true value and
we applied this in the interpretation of results. The four possible
ratings were: high, moderate, low and very low. A rating of high
quality of evidence implies that we are confident in our estimate
of effect and that further research is very unlikely to change our
confidence in the estimate of effect. A rating of very low quality
implies that any estimate of effect obtained is very uncertain.
TheGRADE approach rates evidence fromRCTs that do not have
serious limitations as high quality. However, several factors can
lead to the downgrading of the evidence to moderate, low or very
low. The degree of downgrading is determined by the seriousness
of these factors:
• study limitations (risk of bias);
• inconsistency;
• indirectness of evidence;
• imprecision; and
• publication bias.
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We included a ’Summary of findings’ table, constructed according
to the recommendations described in Chapter 10 of the Cochrane
Handbook for Systematic Reviews of Interventions (Handbook
2011). We included the following outcomes in the ’Summary
of findings’ table: hearing-specific health-related quality of life,
health-related quality of life, listening ability and adverse effects.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
The search identified 4821 records including papers, reviews, con-
ference abstracts and registered clinical trials, of which 2840 re-
mained after removing duplicates. We discarded 2748 records
based on the title and/or abstract, which left 92 records. We dis-
carded a further 81 records. Of these, we discarded 69 on the ba-
sis that they were not RCTs, 10 because the intervention was not
hearing aids alone, one because the control was not appropriate
according to the protocol, and one record was an ongoing clinical
trial (NCT03002142).
Subsequently, we formally excluded five studies for the reasons
given in Excluded studies. An erratum (McArdle 2006) was associ-
ated with one of the included studies (McArdle 2005). Five studies
were eligible for inclusion in the review (Figure 1). Three stud-
ies reported quantitative data that could be included in the meta-
analyses (Humes 2017; McArdle 2005; Mulrow 1990). Method-
ological information was supplemented by other articles on the
same study for McArdle 2005 by Chisolm 2005, and for Adrait
2017 by Nguyen 2017.
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Figure 1. Study flow diagram.
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Included studies
Design
All five included studies reported using a randomised controlled
(parallel) design. Three studies used a waiting list control group (
McArdle 2005;Melin 1987;Mulrow1990), and the control group
in two studies used placebo hearing aids (Adrait 2017; Humes
2017). All five studies specified that the control group received
the active hearing aid intervention at the end of the randomised
phase, and further follow-up was conducted in all but one study
(Mulrow 1990). Participants in the waiting list groups received
hearing aids (McArdle 2005; Melin 1987; Mulrow 1990), and the
placebo hearing aids were reprogrammed to provide amplification
(Adrait 2017; Humes 2017).
The trial endpoint varied across studies with post-hearing aid fit-
ting outcomes obtained at six weeks (Humes 2017; Melin 1987),
two months (McArdle 2005), 16 weeks (Mulrow 1990), and six
months (Adrait 2017). None of the studies reported long-term
outcomes of over one year.
Setting
Three studies were published between 1987 and 2005 (McArdle
2005; Melin 1987; Mulrow 1990), and two were published in
2017 (Adrait 2017;Humes 2017). Two studieswere set inVeterans
Association clinics in the USA (McArdle 2005; Mulrow 1990),
two in university clinics in the USA and Sweden (Humes 2017;
Melin 1987), and one in a hospital setting in France (Adrait 2017).
Population and sample size
Age, sex and hearing loss were reported at the group level for
all studies except Melin 1987, which reported these data at the
participant level. The total sample size for the included studies was
825.
All the studies recruited older adult participants, with themean age
in individual studies ranging between 69 and 83 years. Two stud-
ies involved military personnel and had almost exclusively male
participants (McArdle 2005 98%; Mulrow 1990 99%), whereas
in the other studies males accounted for between 33% and 57%
of the samples. All reported mean thresholds were within the mild
to moderate hearing loss range of this review’s inclusion criteria as
described in Types of participants. The frequencies at which mean
hearing thresholds were reported varied across studies. All studies
had hearing loss as an inclusion criterion but the frequencies and
hearing levels used to define the inclusion criteria varied across
studies. It is possible that the military veterans were at increased
risk of having noise-induced hearing loss. This is typically shown
by a notch in the pure-tone audiogram around 4 kHz (i.e. thresh-
olds close to that frequency would be better at adjacent frequen-
cies). There was no evidence of noise-induced hearing loss in the
group audiometric results in McArdle 2005, and the presence of
noise-induced hearing loss could not be determined in Mulrow
1990. The participants in Humes 2017, who lived independently
in the community, showed no evidence of noise-induced hearing
loss in the group audiometric results. The participants in Adrait
2017 all had a diagnosis of Alzheimer’s disease. Two studies used
normal cognitive function based on theMini-Mental State Exam-
ination as an inclusion criterion (Humes 2017; McArdle 2005),
and those with disabling comorbid conditions were excluded from
Mulrow 1990.
Interventions and comparisons
The intervention in each study was acoustic hearing aids, which
met the inclusion criteria of this review as described in Types
of interventions. Three studies used bilateral hearing fittings (
Adrait 2017; Humes 2017; McArdle 2005), and in the two early
studies hearing aids were fitted to one ear only in 95% and 97%
participants respectively (Melin 1987;Mulrow 1990). Two studies
reported using in-the-ear hearing aids (McArdle 2005; Mulrow
1990), and three studies used behind-the-ear hearing aids (Adrait
2017; Humes 2017; Melin 1987), with three studies reporting
the manufacturer and model of hearing aid used (Adrait 2017;
Humes 2017; Melin 1987). Fully digitally programmable hearing
aids were used in two studies (Adrait 2017; Humes 2017), with
both digital or analogue hearing aids used by McArdle 2005.
Humes 2017 used two programmingmethods for the intervention
group. The hearing aids for the Audiology Best practice group
were programmedusing real-earmeasurements according toNAL-
NL2, whereas the hearing aids for the Consumer Decides group
were preset to three common audiogram configurations, and the
participants chose which programme they preferred. The two early
studies did not report the technology type (Melin 1987; Mulrow
1990). Three studies used awaiting list comparison group until the
first treatment period was completed (McArdle 2005;Melin 1987;
Mulrow 1990), and two studies used placebo hearing aids as the
comparison (Adrait 2017;Humes 2017), whichwere programmed
to provide no gain so as to be as acoustically transparent as possible.
Outcomes
Adrait 2017 is one of a series of papers reporting the results of a
clinical trial aimed at studying the effects of bilateral hearing aids
in patients with age-related hearing loss and Alzheimer’s disease
(AlzheimerDisease, Presbycusis andHearingAids, ADPHA study)
on the cognitive, behavioural, quality of life and economic aspects.
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There were no hearing-specific health-related quality of life or
listening ability outcomes measured. Apart from adverse effects,
this study did not use any of the outcome measures pre-specified
in this review (Types of outcome measures).
Primary outcomes
Three studies reported hearing-specific health-related quality of
life using theHHIE (Humes 2017;McArdle 2005;Mulrow1990).
In addition to the HHIE, Mulrow 1990 also used the Quantified
Denver Scale of Communication (QDS). Using the outcome hi-
erarchy defined in Primary outcomes, we only included theHHIE
data from Mulrow 1990 in the meta-analyses.
Only one study measured adverse effects (Adrait 2017); no adverse
effects related to pain were reported.
Secondary outcomes
Health-related quality of life was reported by three studies (Adrait
2017; McArdle 2005; Mulrow 1990). Two studies used outcome
measures that were generic to the clinical population being as-
sessed: McArdle 2005 used the WHO-DAS II and Mulrow 1990
used the Self-Evaluation of Life Function (SELF).
Adrait 2017 used a disease-specific health-related quality of life
measure for patients with Alzheimer’s disease (Alzheimer’s Dis-
ease Related Quality of Life, ADRQL; Rabins 1999). Data for
the ADRQL were collected from the caregivers, rather than the
patients. Therefore, this was not an outcome measure of interest
pre-specified in this review.
Listening ability was reported in three studies. Humes 2017 used
the Profile of Hearing Aid Performance (PHAP; Cox 1990),
McArdle 2005 used the Abbreviated Profile of Hearing Aid Bene-
fit (APHAB) and Melin 1987 used a hearing ability scaling assess-
ment. We did not include the hearing ability scaling assessment,
which is not a validated measure, in the meta-analysis as not all
the data required were available in the paper and were no longer
available.
Only one study measured adverse effects (Adrait 2017); no adverse
effects related to noise-induced hearing loss were reported.
Excluded studies
Details of the five studies that we excluded after clarification of the
methods used are shown in Characteristics of excluded studies.
Risk of bias in included studies
Two authors (MF, PK) critically reviewed the methodology of the
included studies. We contacted the authors from all five included
studies to further establish aspects of risk of bias that were unclear
from the full article. We received responses from four authors
(Adrait 2017; Humes 2017; McArdle 2005; Melin 1987). The
’Risk of bias’ summary for the included studies is shown in Figure
2. One study showed a low risk of bias in six categories (Adrait
2017), two studies showed a low risk of bias in four categories
(Humes 2017; Mulrow 1990), and two studies showed a low risk
of bias in three categories (McArdle 2005; Melin 1987).The ’Risk
of bias’ graph presented as percentages across all studies is shown
in Figure 3. Further details are described below.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Random sequence generation
We judged all five included studies to be at a low risk of bias due
to sequence generation.
Allocation concealment
We judged three studies to be at low risk of bias due to al-
location concealment as a remote allocation service or sealed,
opaque envelopes were used (Adrait 2017; Melin 1987; Mulrow
1990). There was insufficient information to make a judgement
for McArdle 2005, and we judged Humes 2017 to be at high risk
of bias because the randomisation list was visible to the clinical
trial co-ordinator who also allocated participants to the treatment
or comparator group.
Blinding
Until recently, the nature of hearing aids as an intervention has
led to substantial difficulty in designing trials that aim to control
for performance bias. In addition, the visibility of hearing aids
increases the risk of detection bias when a researcher measures
outcomes. Thus, we judged all the studies published during or
before 2005 that used waiting list controls to be at high risk for
both performance and detection bias (McArdle 2005;Melin 1987;
Mulrow 1990). The use of placebo hearing aids allows blinding
of participants and personnel and blinded assessment of outcomes
if they are visibly identical to active hearing aids and the fitting
procedure for active and placebo devices is indistinguishable to
the participant. These criteria were met by Adrait 2017, which we
judged to be at low risk of performance and detection bias. The
Humes 2017 study also used placebo devices but we judged this
to have an unclear risk of performance and detection bias as there
was potential for participants to be unblinded due to contact with
the clinical trial co-ordinator who was not blinded to allocation.
Incomplete outcome data
We judged attrition bias to be low for three studies (Humes 2017;
McArdle 2005; Mulrow 1990), as dropouts were clearly reported
and dropout numbers were low and were equal across both the
intervention and comparator groups. The reasons for dropouts
were generally not related to the intervention. McArdle 2005 used
imputation to account formissing data due to dropouts. There was
insufficient information about the other two studies to assess the
risk of bias (Adrait 2017; Melin 1987), which led to a judgement
of unclear risk.
Selective reporting
We judged all five included studies to be at low risk of selective
reporting. Two studies published study protocols and reported
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the stated outcomes (Adrait 2017; Humes 2017). Although no
protocols had been published prior to the completion of two of
the older studies (McArdle 2005; Mulrow 1990), the reported
outcomes followed the rationale of the studies. Contact with the
authors of Melin 1987 indicated that all outcomes measured had
been included.
Other potential sources of bias
Three of the included studies had the comparator group on a wait-
ing list (McArdle 2005; Melin 1987; Mulrow 1990), and all of
these studies had specified that all patients would receive hearing
aids at the end of the randomised phase. Studies using waiting list
controls have a risk of overestimating the benefit of an interven-
tion, especially if participants perceived that the reported outcomes
could determine their eligibility for an intervention (Furukawa
2014). As all the participants were aware that they would receive
the interventions at the end of the study, we thought that the risks
were less clear in this case (unclear risk of bias).
Effects of interventions
See: Summary of findings for the main comparison Hearing
aids versus no hearing aids for mild to moderate hearing loss in
adults
See: Summary of findings for the main comparison.
For the McArdle 2005 study, we extracted data from Table 3,
except the Hearing Handicap Inventory for the Elderly (HHIE)
data from the control group at the two-month follow-up, which
we took from the table in the Erratum (McArdle 2006). Humes
2017 did not report the six-week follow-up results, so we obtained
these from the study dataset that was sent at our request. We
directly extracted data from Mulrow 1990. Data from Melin
1987 and Adrait 2017 were not included in the meta-analysis (see
Characteristics of included studies).
Comparison: hearing aids versus no hearing aids
Primary outcome measures
1. Hearing-specific health-related quality of life
The HHIE at study endpoint was used to measure hearing-spe-
cific health-related quality of life in all three studies included in a
meta-analysis. Mean differences (MDs) and their 95% confidence
intervals (CIs) are shown in Analysis 1.1 (Figure 4).
Figure 4. Forest plot of comparison: 1 Hearing aids versus no/placebo hearing aids, outcome: 1.1 Hearing-
specific health-related quality of life. Assessed using Hearing Handicap Inventory for the Elderly (HHIE) in all
studies.
The random-effects meta-analysis showed a significant overall ef-
fect that favoured hearing aids over the unaided/placebo com-
parison (scale range 0 to 100) (MD -26.47, 95% CI -42.16
to -10.77; 722 participants; three studies) (moderate-quality evi-
dence) (Analysis 1.1). We observed considerable heterogeneity (I
2 = 97%), which was statistically significant (Chi2 = 63.84, df =
2, P < 0.00001). We conducted an unplanned subgroup analy-
sis (Veterans Association setting, mostly male, in-the-ear hearing
aids, waiting list control versus community setting, male-female
balance, behind-the-ear hearing aids, placebo control study) to ex-
plore this statistical heterogeneity. This showed statistically signif-
icant subgroup effects (P < 0.00001). The MD was -33.48, (95%
CI -36.72 to -30.23; 568 participants; two studies; I2 = 4%) for
the veterans subgroup (McArdle 2005;Mulrow 1990), and -10.54
(95% CI -15.26 to -5.82; 154 participants) for the community
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setting subgroup (Humes 2017).
The Quantified Denver Scale of Communication (QDS) results
from Mulrow 1990 were not included in the meta-analysis as our
protocol specified a hierarchy of inclusion in which theHHIE had
a higher priority. However, the QDS also indicated a significant
effect favouring hearing aids (scale range 0 to 100) (MD -26.5,
95% CI -33.6 to -19.4; 188 participants).
2. Adverse effects
Only one study (n = 48) measured adverse effects (Adrait 2017),
and no adverse effects related to pain were reported (very low-
quality evidence).
Secondary outcome measures
1. Health-related quality of life
Health-related quality of life at study endpoint wasmeasured using
the World Health Organization Disability Assessment Schedule
(WHO-DAS) II (McArdle 2005) and the Self-Evaluation of Life
Function (SELF) (Mulrow 1990). A random-effects meta-analysis
showed a significant overall effect that favoured hearing aids over
the unaided/placebo comparison (standardised mean difference
(SMD) -0.38, 95% CI -0.55 to -0.21; 568 participants; two stud-
ies, I2 = 6%) (moderate-quality evidence) (see Analysis 1.2; Figure
5).
Figure 5. Forest plot of comparison: 1 Hearing aids versus no/placebo hearing aids, outcome: 1.2 Health-
related quality of life.
2. Listening ability
Listening ability at study endpoint was measured using the Pro-
file of Hearing Aid Performance (PHAP) in Humes 2017 and the
Abbreviated Profile of Hearing Aid Benefit (APHAB) in McArdle
2005. A random-effects meta-analysis showed a significant overall
effect that favoured hearing aids over the unaided/placebo com-
parison (SMD -1.88, 95% CI -3.24 to -0.52; 534 participants;
two studies) (moderate-quality evidence) (Analysis 1.3; Figure 6).
We observed considerable heterogeneity (I2 = 97%), which was
statistically significant (Chi2 = 31.12, df = 1, P < 0.00001). The
unplanned subgroup analysis showed statistically significant (P <
0.00001) subgroup effects, where McArdle 2005 had a SMD of
-2.57 (95% CI -2.84 to -2.30; 380 participants) and Humes 2017
had a SMD of -1.18 (95% CI -1.54 to -0.81; 154 participants).
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Figure 6. Forest plot of comparison: 1 Hearing aids versus no/placebo hearing aids, outcome: 1.3 Listening
ability.
3. Adverse effects
Only one study (n = 48) measured adverse effects (Adrait 2017),
and no adverse effects related to noise-induced hearing loss were
reported (very low-quality evidence).
D I S C U S S I O N
Summary of main results
For hearing-specific health-related quality of life where participa-
tion is the key domain (primary outcome measure), we found ev-
idence that hearing aids had a large beneficial effect in reducing
participation restrictions. Our confidence in the quality of the evi-
dence for hearing-specific health-related quality of life was moder-
ate due to high risk of bias (see Summary of findings for the main
comparison). Significant differences in the size of effects were ap-
parent across studies; the effects reported by the two individual
Veterans Association (VA) studies were similar (McArdle 2005;
Mulrow 1990), and more than twice the size of the effect reported
by Humes 2017. However, all three studies individually reported
large effects (standardised mean difference (SMD) > 0.70) that
favoured hearing aids, meaning that while further evidence may
change the size of the overall effect on hearing-specific health-re-
lated quality of life, we have high confidence in the magnitude
and direction of the effect.
For health-related quality of life (secondary outcome measure)
there was evidence of a small beneficial overall effect of hearing
aids compared to the unaided/placebo condition. Two different
outcome measures were used. One study reported a significant
benefit of hearing aids compared to the unaided/placebo condi-
tion using the World Health Organization Disability Assessment
Schedule (WHO-DAS II) (SMD -0.44, 95% confidence interval
(CI) -0.65 to -0.24; 380 participants), and another study reported
no significant effect of hearing aids using the Self-Evaluation of
Life Function (SELF) (SMD -0.26, 95% CI -0.55 to 0.03; 188
participants). Heterogeneity was low. Our confidence in the qual-
ity of the evidence for health-related quality of life was moderate
due to high risk of bias (see Summary of findings for the main
comparison).
For listening ability (secondary outcome measure), there was a
large beneficial effect of hearing aids when compared to the un-
aided/placebo condition. The two studies used different outcome
measures with one, Abbreviated Profile of Hearing Aid Benefit
(APHAB), being an abbreviated versionof the other (PHAP). Both
measures revealed large beneficial effects that favoured the use of
hearing aids. Our confidence in the quality of the evidence for lis-
tening ability was moderate due to high risk of bias (see Summary
of findings for the main comparison), although we have high con-
fidence that the effect was both large and beneficial.
Adverse effects associated with hearing aids were measured in only
one study but no adverse effects were reported that related to pain
or noise-induced hearing loss, so it was not possible to comment
on the reported benefits against harms.
Overall completeness and applicability of
evidence
Five randomised controlled trials (RCTs) met the inclusion criteria
for this review. Three studies assessed hearing-specific health-re-
lated quality of life using measures that fit within our pre-defined
hierarchy of self-report outcome measures, of which one measure
(theHearingHandicap Inventory for the Elderly,HHIE) was used
in all three studies. High heterogeneity and subgroup differences
for the HHIE results stem from the Humes 2017 study of older
adults living in the general community, in which a smaller effect
was observed than was found in the two VA studies (McArdle
2005; Mulrow 1990). The participants in the Humes 2017 study
had amore evenmale-female split (57:43), had better average hear-
ing thresholds, were provided with behind-the-ear hearing aids for
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a cost, and the comparison group received placebo hearing aids.
In contrast, the participants in the VA studies were almost exclu-
sively male veterans who may have experienced gunfire or explo-
sive noise that may have resulted in noise-induced hearing loss
and the possibility of compensation claims, had poorer hearing,
were provided with in-the-ear hearing aids at no cost, and were
compared to a waiting list (passive control) group. These partici-
pant and methodological differences were likely to account for the
differences in the estimated size of the effects between the studies
for both the hearing-specific health-related quality of life and lis-
tening ability outcomes. As there were numerous differences be-
tween these two groups of participants (military veterans versus
community dwellers), we considered whether it was appropriate
to pool the studies. On the basis that recommendations for the
clinical management of hearing loss using hearing aids would not
differ between these two groups, we concluded that the data from
the studies should therefore be pooled. The choice of outcome
measure to assess health-related quality of life was inconsistent, al-
though heterogeneity in the reported effects was low. The WHO-
DAS II used in theMcArdle 2005 study has since been superseded
by theWHO-DAS 2.0 (WHO 2012b), which directly links to the
International Classification of Functioning, Disability and Health
(ICF) framework.
We did not include cognition as an outcome in the protocol be-
cause of the wide variety and uncertainty of definitions of spe-
cific domains within the broader context of cognition (e.g. at-
tention, memory, processing speed). The Short Portable Mental
Status Questionnaire and Geriatric Depression Scale measures re-
ported in one included study (Mulrow 1990), alongside a raft of
measures related to Alzheimer’s disease in another study (Adrait
2017), were not specified in the protocol, and we did not analyse
or report the results. Mulrow 1990 reported significant improve-
ments in the hearing aid group on both measures, whereas there
were no group differences for any of the measures reported by
Adrait 2017.
The planned subgroup analyses (age, sex and degree of hearing
loss) could not be performed as data from these subgroups were
not reported.Outcomes weremeasured for short-to-medium term
follow-up only (six weeks to sixmonths), with no studies reporting
long-term outcome at more than one year for either intervention
or control groups separately. In terms of completeness, there are
a limited number of RCTs, a preponderance of participants who
were men who had poorer hearing, inconsistency in the choice
of outcome measures to assess health-related quality of life and
listening ability, and inconsistency in the choice of comparator
(waiting list versus placebo control).
In terms of applicability, all participant samples were reported to
have mild to moderate hearing loss. The three studies included
in the meta-analyses represented the majority of the participants
from the included studies (n = 738; 89%). However, two of these
study samples (n = 574) were overwhelmingly male military veter-
ans (97% and 99%) who received their hearing aids free of charge,
although there is evidence that the price of hearing aids does not
affect outcomes (Humes 2017). Generalisability to other non-mil-
itary populations that would certainly include a greater proportion
of women represents a limitation, which these studies acknowl-
edged, and may reflect the size of the effects on hearing-specific
health-related quality of life and listening ability. There was also
variability in whether hearing aids were fitted unilaterally or bilat-
erally. Three of the studies had exclusion criteria that were specific
to other comorbid conditions, such as cognitive impairment (two
studies specifically screened for this using the Mini-Mental State
Examination), which could also limit applicability of the findings
to general clinical populations, such as those with dementia. Al-
though Adrait 2017 reported no effect of hearing aids in their
population of patients with Alzheimer’s disease, the outcomes in
that study differed to those specified in our review.
Finally, only two of the five included studies set out specifically
to examine whether hearing aids improved quality of life in those
who had hearing loss (Adrait 2017; Mulrow 1990), but one of
these recruited only people with Alzheimer’s disease. The primary
aim of McArdle 2005 was to assess the properties of the WHO-
DAS II as an outcome measure by examining its responsiveness to
the effects of hearing aids. The Melin 1987 study was primarily
designed to examine hearing aids as an intervention for people
with tinnitus, and the Humes 2017 study focused on different
service delivery models.
Quality of the evidence
We considered the quality of evidence for the primary outcome
measure (hearing-specific health-related quality of life) and sec-
ondary outcome measures (health-related quality of life and lis-
tening ability), as assessed by the GRADE system, to be moderate.
We downgraded the quality of the evidence by one level because
all studies contributing data to these outcomes had either a rating
of unclear and/or high risk bias in at least one of the domains of
selection bias, performance and/or detection bias (see Summary
of findings for the main comparison).
All five included studies were RCTs. We judged three studies to
be at high risk of performance and detection bias (McArdle 2005;
Melin 1987; Mulrow 1990). These biases are recognised widely
to be problematic in hearing aid intervention studies as blinding
of patients and assessors can be difficult to achieve. Although
Humes 2017 used a placebo hearing aid comparison to control for
these biases, the potential for unblinding led to our judgements of
unclear risk. However, the use of placebo hearing aids with zero-
gain prescriptions adopted by both Adrait 2017 and Humes 2017
does demonstrate that it is now possible to blind participants and
outcome assessors in hearing aid trials.
We considered downgrading the evidence for the effects of hear-
ing aids on hearing-specific health-related quality of life and lis-
tening ability due to both inconsistency and indirectness. There
were concerns over inconsistency because of the observed statis-
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tical heterogeneity between VA studies (McArdle 2005; Mulrow
1990) and the study ofHumes 2017 conducted in the community
setting. Concerns arose over indirectness both because the anal-
yses included data from male military veterans and also because
of the short follow-up period in Humes 2017 (six weeks). We
took the decision not to downgrade due to either inconsistency
or indirectness as all studies individually reported large beneficial
effects of hearing aids on both outcomes, regardless of whether
they had been conducted in the military or community settings
and regardless of the duration of follow-up. Thus, the observed
heterogeneity did not reduce our confidence in the estimates of
these effects.
Finally, we considered downgrading the evidence for health-re-
lated quality of life due to indirectness. Both studies included in
the analysis had samples that were almost exclusively male military
veterans (McArdle 2005; Mulrow 1990). However, we did not
downgrade the evidence because the estimates of the effect were
similar across the two studies and heterogeneity was low despite
numerous other differences in their samples and designs (i.e. dif-
ferent outcome measure, follow-up period and hearing aid style
and number fitted). Our confidence in the size of the effect was
therefore not reduced.
Limitations of the evidence reviewed were the numerous method-
ological and sampling differences between the two veteran studies
(McArdle 2005; Mulrow 1990) and the other included studies,
and the lack of long-term outcomes (i.e. greater than one year).
There were also inconsistencies in the reporting of the studies and
clarification on methodological details had to be sought from the
authors of all five studies, with four providing information that
was not published. Two of the studies were published before the
2001 CONSORT guidelines yet only one out of the other three
studies that could have feasibly been able to follow these guidelines
reported the study to that standard (Humes 2017).
Potential biases in the review process
The electronic searches for this review were comprehensive, with
a second search carried out within two months of submission to
ensure an up-to-date review. The protocol defined the review pro-
cess and the roles of the authors, and each source was indepen-
dently reviewed by two authors. Inclusion did not require specific
outcome tools.
We revised the inclusion criteria relating to the types of participants
due to concerns that the original criteria stated in the protocol had
the potential to bias the study selection process (see Differences
between protocol and review).
Although we revised the inclusion criteria for Types of participants
part-way through the review, we did this with the important ratio-
nale of avoiding a potential bias where studies that were reported
in less detail (e.g. group mean hearing threshold data or qualitative
descriptions) were more likely to be included than those studies
that either reported inmore detail or provided us with participant-
level data. To minimise the risk of bias in this process, the revised
definition for Types of participants and the final decisions about
which studies were eligible for inclusion in the review were subject
to independent review by an external expert committee to ensure
that this was appropriate for the review question.
Agreements and disagreements with other
studies or reviews
This review is consistent with the conclusions of a previous system-
atic review on hearing aids (Chisolm 2007). Both reviews conclude
that hearing aids improve hearing-specific health-related quality of
life compared to no hearing aids. However, whereas Chisolm 2007
identified a lack of evidence for more general effects on health-
related quality of life in people with hearing loss, in our review we
showed a small beneficial effect. These reviews differ in a number
of methodological details. The current review includes only ran-
domised controlled trials, whereas Chisolm 2007 included ran-
domised and non-randomised trials. Chisolm 2007 used the Scot-
tish Intercollegiate Guideline Network (SIGN) grading system
(Harbour 2001), and included two studies that met the highest
level of evidence (level 1, RCTs) (Mulrow 1990; Yueh 2001). We
did not include the Yueh 2001 study as the randomisation took
place after the participants had been allocated to either hearing
aids or no hearing aids on the basis of whether they were eligible
to receive hearing aids or not. Our review included the McArdle
2005 study, which had not been published at the time theChisolm
2007 review was conducted, and we included the study by Melin
1987. The other main differences between the reviews were that
our review was able to include three generally well-designed RCTs
in the meta-analyses and used a pre-defined hierarchy of outcome
measures for each outcome domain.
A more recent review on the benefit of hearing aids for patients
with mild sensorineural hearing loss concludes that there is ev-
idence that hearing aids benefit adults with mild sensorineural
hearing loss (Johnson 2016). None of the studies included in this
review were RCTs, and so we cannot compare the results and con-
clusions of that review with ours.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is evidence of moderate quality that hearing aids improve
participation, overall health-related quality of life and listening
ability in adults with mild to moderate hearing loss. If the goals
and needs of an individual with hearing loss are to improve their
listening abilities and, in doing so, improve their participationwith
others in everyday life and their health-related quality of life more
generally, then hearing aids are an appropriate intervention. The
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evidence is generally compatible with the widespread provision
of hearing aids as the first-line clinical management option in
those individuals who seek help. Evidence not considered by this
review also suggests that self-management of hearing aids should
be considered alongside clinical management to improve hearing-
related participation and communication over the short term (
Barker 2016), and increase hearing aid use (Ferguson 2016).
In light of an absence of evidence for the long-term effects of
hearing aids on any of the reported outcome measures, outcomes
should be monitored up to at least one year post-fitting to deter-
mine whether short-term effects are sustained, and whether ad-
ditional intervention may be required. The fact that hearing aids
are in widespread use as an intervention for hearing loss means
that questions about long-term effects could be usefully addressed
by a synthesis of evidence from large-scale cohort studies. Such a
synthesis would be enabled through the consistent collection and
reporting of outcomes at consistent time points following hearing
aid fitting.
Implications for research
Well-designed trials are needed to establish whether the effects of
hearing aids vary according to age, gender, type of hearing aid, and
degree and type of hearing loss. Trial populations should be sam-
pled to be representative of typical first-time hearing aid recipients
in terms of gender, age and hearing thresholds. Trial sample sizes
need to be large enough to allow subgroup analysis (e.g. compar-
ison of men and women) and to identify the extent of effects of
hearing aids within specific patient groups. The reporting of trials
also needs to be sufficiently detailed to permit the extraction of
data within such subgroups. Trial sample sizes need to be large
enough to achieve sufficient statistical power to detect the mini-
mal clinically important difference (MCID) in the primary out-
come measure. However, further research is needed to determine
the MCID on outcome measures relevant to hearing aids as there
is currently an absence of such information. Fitting hearing aids
to standard fitting protocols and hearing aid prescriptions (e.g.
NAL-NL2) using probe tube microphones to obtain well-fitted
hearing aids is also necessary to ensure hearing aids are functioning
as intended.
The choice of outcome measure for assessing the effects of hearing
aids on broader aspects of health should be considered carefully.
Generic measures of health that include relevant domains such
as communication (e.g. WHO-DAS 2.0) may be more likely to
show effects of hearing aids thanmeasures that do not include such
domains. To demonstrate cost-effectiveness of hearing aid provi-
sion, and for comparison against other healthcare conditions and
interventions, the use of preference-based instruments should also
be considered. These measures need to be selected based on evi-
dence for their validity in evaluating hearing-related interventions
and their sensitivity to hearing-related changes in health-related
quality of life. For example, the Health Utilities Index Mark III
(HUI-3) has been shown to be more sensitive to improvements in
quality of life resulting from hearing aids compared to both the
EQ-5D and the SF-36, which are less sensitive to hearing-related
changes in health (Barton 2004; Davis 2007; Joore 2003).
Greater consistency in the choice of outcomemeasures across stud-
ies would enable direct comparisons of the effects of hearing aids
and facilitate meta-analyses. The development of a core outcome
set for use in auditory rehabilitation research would not only en-
courage consistency in the measurement and reporting of out-
comes (Barker 2016); if selected through an appropriate process,
it would also ensure that outcomes are meaningful to patients and
clinicians. There is also a need for greater consistency in the time
points at which patients are followed up after hearing aid fitting,
withmore emphasis on longer-term follow-up outcomesmeasured
at greater than one year.
Measures of cognition should be included in future review updates
with a proposed hierarchy based on publications from current on-
going systematic reviews (e.g. Loughrey 2015) and expert consen-
sus (e.g. Pichora-Fuller 2016). The reporting of adverse effects in
our included studies was limited and inconsistent and therefore
should be given specific attention in the design and reporting of
future hearing aid trials. Hearing aid take-up and use was not an
outcome in this review as we were specifically examining the dif-
ference between the aided and unaided conditions. However, there
is value in obtaining a metric for hearing aid use as a secondary
measure in future studies in any aided groups. This should be
based on a relevant model of health behaviour to help determine
behaviours that effectively promote hearing aid use, and how it
might be improved (Barker 2016; Coulson 2016).
Further studies should be designed to minimise the risk of perfor-
mance and detection bias that is inherent inmost hearing aid trials.
Blinding the patient to the intervention is difficult to achieve with
hearing aids but can be achieved by programming hearing aids to
provide no amplification, which may be acceptable where there is
genuine equipoise around their effectiveness. However, care must
still be taken to ensure that such placebo hearing aids cannot be
distinguished from active hearing aids based on either their visual
appearance or the manner in which they are fitted. Blinding of
outcome assessors should be incorporated into the design of future
trials and particular care should be taken to ensure both patient
and outcome assessor remain blinded when collecting patient-re-
ported outcomes. For example, self-reported outcome data could
be obtained via telephone rather than through self-completion of
questionnaires on paper or through interview; telephone admin-
istration has the additional benefit of increasing the test-retest re-
liability of patient-reported outcome measures (Weinstein 1997).
Reporting of all future trials should follow the CONSORT guide-
lines (CONSORT 2010).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Adrait 2017
Methods 2-arm, double-blinded, multi-centre, with 6 months duration of treatment and follow-
up
Participants Location: France, multi-centre sites
Setting of recruitment and treatment: hospital setting
Sample size:
• Number randomised: 51*, 48 fitted with hearing aids (22 intervention, 26
control)
• Number completed: 38 (18 in intervention, 20 in comparison; attrition n = 10
(20.8%), caregiver withdrawal n = 1, caregiver or legal representative withdrawal n = 2,
voluntary withdrawal n = 3, investigator exclusion n = 1, protocol deviation n = 2,
serious adverse event not related to the trial n = 1). *n = 3 not fitted, 2 in active group,
1 in placebo group (erroneously included (unilateral hearing loss) n = 1, voluntary
withdrawal n = 2)
Participant (baseline) characteristics:
• Age: intervention, mean 83.0 years (SD 6.2); control, mean 82.3 years (SD 7.2)
• Gender: intervention, 8 male, 14 female; control, 11 male, 15 female
• Main diagnosis: hearing loss (pure-tone average (PTA) averaged across 0.5, 1.0, 2.
0, 4.0 kHz; bilateral): intervention 50.6 dB HL (SD 11.4); control mean 47.2 dB HL
(SD 9.6)
• Other important effect modifiers: all patients had Alzheimer’s disease (see
inclusion criteria)
Inclusion criteria: probable diagnosis of AD according to DSM-IV and NINCDS-
ADRDA, aged >= 65 years, Mini-Mental State Examination score between 10 and 28,
bilateral SNHL (between 21 and 80 dB HL), not worn hearing aids for previous 2 years,
tolerates hearing aids for at least 1 hour per day, living with an informal, motivated
caregiver
Exclusion criteria: non-AD dementia (medical history, clinical elements, biological/
medical imaging data examples given), recent introduction of cognitive-behavioural
treatment, change in dosage of treatments prior to the study (cholinergic and meman-
tine (< 6 m), psychotropic medication (< 2 m)), recent change in dosage of treatments
(cholinergic and memantine (< 2 m), (cholinergic and memantine (< 1 m)), break or
loss of hearing aids 2 or more times during study
Interventions Intervention group (n = 18): active hearing aids (SAVIA andVALEO (Phonak), behind-
the-ear, fully digital, bilateral fits. Fitted according to Phonak Digital (proprietary fitting
algorithm derived from NAL-NL1)
Comparator group (n = 20): placebo hearing aids, programmed to minimal amplifica-
tion so patients could just hear 25 dB SL white noise (30 dB on average), to compensate
for the occlusion effect
Use of additional interventions (common to both treatment arms): at 6 months,
placebo hearing aids were activated; both groups used active hearing aids for 12 months
study endpoint
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Adrait 2017 (Continued)
Outcomes Primary outcome: Neuropsychiatric Inventory
Secondary outcomes: Instrumental Activities of Daily Living, Zarit, Alzheimer Disease
Related Quality of Life, Duke health profile (simplified, items 15 and 16 on social
interactions) for patient and caregiver. Adverse effects
None of these outcome measures were relevant or appropriate to the outcome domains
of interest specified in this review
Funding sources French Ministry of Health (Clinical Research Hospital Program 2005, PHRC 2005-
APN) and the Fondation Mederic Alzheimer, Paris
Declarations of interest Nothing to disclose
Notes All participants had a probable diagnosis of Alzheimer’s disease and so this was a distinctly
different clinical population from typical first-time hearing aid users
Hearing aids provided by Phonak at no cost to the participant
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation used a pre-established and
well-balanced list based on chronological
order of inclusion.Usedblocks of 6patients
Allocation concealment (selection bias) Low risk Randomisation procedure was centralised
at a clinical research unit remote from the
study setting and conducted by research
methodologists independent of the study
team
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo hearing aids used so participants
were blinded. Only the hearing aid special-
ist fitting the devices knew the randomi-
sation group of the participants (required
to apply the appropriate gain prescription)
. Unlikely that blinding could be broken
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessor and participants were
blinded.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Dropouts and withdrawals were docu-
mented but unclear why some data from
the remaining participants on some out-
comes were not reported
Selective reporting (reporting bias) Low risk Data on all outcomes in the published
study protocol (NCT01788423) were re-
29Hearing aids for mild to moderate hearing loss in adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Adrait 2017 (Continued)
ported
Other bias Low risk Study appears to be free of other sources of
bias.
Humes 2017
Methods 3-arm, double-blinded, single-centre, parallel-arm RCT, with 6 and 10 weeks duration
of treatment and follow-up
Participants Location: USA (Indiana)
Setting of recruitment and treatment: university research clinic
Sample size:
• Number randomised: 164* (53 intervention (audiology best practice, AB), 55
intervention (consumer decides, CD), 55 control (placebo).
• Number completed: 154 (53 intervention (audiology best practice, AB), 50
intervention (consumer decides, CD), 51 control (placebo); attrition n = 10 (6.0%), ear
or health problems n = 3, fitting problem or non-use n = 2, unable to complete hearing
aid selection n = 4, *withdrawal after randomisation and before the fitting session n = 1)
Participant (baseline) characteristics:
Age: mean 69.1 years (SD 6.1)
Gender: 92 male, 72 female
Main diagnosis: hearing loss (PTA averaged across 0.5, 1.0, 2.0 kHz = 28.1 dB HL (SD
8.0); high frequency PTA averaged across 1.0, 2.0, 4.0 kHz = 38.8 dB HL (SD 7.9)
Other important effect modifiers: none
Inclusion criteria: age 55 to 79 years, English as native language, MMSE score > 25,
no prior hearing aid experience, pure-tone audiometry (air) consistent with age-related
hearing loss within the fitting guidelines of this study, bilaterally symmetrical hearing
loss
Exclusion criteria: presence of a medically treatable ear condition, bilateral, flat tym-
panograms, known fluctuating or progressive HL, presence of cognitive, medical or lan-
guage-based conditions that limit ability to complete all test procedures, currently or
recently taking platinum-based cancer drugs or mycin-family antibiotics, previously di-
agnosed with either multiple sclerosis or Ménière’s disease, failure to seek or waive medi-
cal evaluation and clearance following hearing evaluation, unwillingness to be randomly
assigned to a treatment group
Interventions Intervention group, AB and CD (n = 108): active hearing aids (ReSound Alera Mini)
, behind-the-ear, fully digital. Bilateral fits. Fixed directional microphones, dynamic
feedback suppression and noise reduction unclear if enabled. AB: fitted using real-ear
measurements according to theNAL-NL2 target, with adjustments as necessary. Verified
via real ear measurements using Audioscan Verifit system. CD: 3 possible prescriptions
based onNAL-NL2fit to the 3most commonpatterns of hearing loss among older adults
in the US. Different programmes applying different constant gains across all frequencies
(gain values based on chosen typical prescription)
Comparator group (n = 51): placebo hearing aids (ReSound Alera Mini), behind-the-
ear, fully digital. Bilateral fits. Fixed directional microphones (n = 20), omni-directional
microphones (n = 23), dynamic feedback suppression and noise reduction enabled.
Programmed to achieve 0 dB insertion gain to control for any occlusion effect. Verified
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Humes 2017 (Continued)
via real ear measurements using Audioscan Verifit system
Use of additional interventions (common to both treatment arms): none up to 6
weeks post-baseline, then the CD group was offered AB-delivered hearing aids for a
further 4 to 5 weeks trial
Outcomes Primary outcome: Profile of Hearing Aid Benefit
Secondary outcomes: Connected Speech Test, Hearing Handicap Inventory for the
Elderly, Hearing Aid Satisfaction Survey
Funding sources National Institute on Deafness and Other Communication Disorders R01 DC011771
Declarations of interest None reported
Notes AB and CD were combined into the intervention group as hearing aids not service deliv-
ery models were of interest. The 6-week follow-up measured the primary and secondary
outcome measures
Participants paid for their hearing aids.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Based on random number generation prior
to study initiation, blocked by unaided
Connected Speech Test performance (low,
medium, high)
Allocation concealment (selection bias) High risk The clinical trial co-ordinator (CTC) allo-
cating patients had access to the randomisa-
tion lists and allocation was not concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk All markings and materials revealing man-
ufacturer or model of the devices were ob-
scured. The CTC was not blinded to pa-
tient allocation and there were several op-
portunities where there was potential for
participants to be unblinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessor (audiologist 4) was
blinded to allocationof intervention group.
However, it is unclear whether all the par-
ticipants remained effectively blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk All dropouts and loss to follow-up de-
scribed and reasonable.
Selective reporting (reporting bias) Low risk Data on all outcomes in the published
study protocol (NCT01788423) were re-
ported. The study authors provided the full
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Humes 2017 (Continued)
data set for this review upon request
Other bias Low risk Study appears to be free of other sources of
bias.
McArdle 2005
Methods 2-arm, non-blinded, multi-centre, parallel-group RCT, with 2 months duration of treat-
ment and follow-up
Participants Location: USA, 4 sites (Tennessee n = 2, Pittsburgh, Florida)
Setting of recruitment and treatment: US veterans awaiting hearing aids for the first
time at Veteran Affairs Medical Centres
Sample size:
• Number randomised: 380 (189 intervention, 191 control)
• Number completed: 362 (176 in intervention, 186 in comparison; attrition n =
18 (4.7%), due to death n = 3, illness n = 4, withdrew consent n = 4, protocol
deviation n = 2, unknown n = 5). Missing data imputed.
Participant (baseline) characteristics:
• Age: mean 69.4 years (SD 9.0)
• Gender: 374 male, 6 female
• Main diagnosis: hearing loss (PTA averaged across 0.5, 1.0, 2.0, 4.0 kHz = 43.17
dB HL)
• Other important effect modifiers: none
Inclusion criteria: PTA at 2.0, 3.0, 4.0 kHz >= 30 dB HL in better hearing ear, Mini-
Mental State Examination pass, eligible for hearing aids, no prior hearing aid experience
Exclusion criteria: conduction or retrocochlear pathology, asymmetry (not defined),
speech recognition in quiet (not defined)
Interventions Intervention group (n = 189): hearing aids (manufacturer not specified), in-the-ear,
analogue or fully digital, fitted 2 weeks post-baseline. Bilateral fits routine. Fitted using
real-ear measurements according to the NAL-R target, with adjustments as necessary.
Fitted 2 weeks post-baseline
Comparator group (n = 191): waiting list controls; no hearing aids up to 10 weeks
post-baseline
Use of additional interventions (common to both treatment arms): none up to 10
weeks post-baseline, then both groups had hearing aids
Outcomes Primary outcomes: none specified
Secondary outcomes: none specified
Reported outcomes: baseline and 2 months post-fitting: WHO-DAS II total (WHO-
DAS II subscales: Communication, Participation), HHIE, APHAB Global
Funding sources Veterans Association
Declarations of interest None noted
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McArdle 2005 (Continued)
Notes 10 weeks after baseline, hearing aids were fitted to the control group and the study
continued to 12 months follow-up
Hearing aids provided at no cost.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Although no information was reported in
the published manuscript, inspection of
the study protocol provided by the authors
showed that stratified randomisation had
been used. Participants were recruited in a
pairs design and coin tossing decidedwhich
group the participant was allocated too (e.
g. heads, Participant A is in the treatment
group)
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Noblinding, therefore patients andperson-
nel were aware of the intervention. Possible
that the hearing aid group were treated dif-
ferently compared to the waiting list group
in other aspects
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding and outcomes were likely to
have been influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk Detailed information provided on attrition
(see Table 2) with reasons, where known.
Missing data were imputed using appropri-
ate methods
Selective reporting (reporting bias) Low risk No published study protocol. However, in-
spection of the protocol provided by the
authors indicates that the published reports
include all expected outcomes
Other bias Unclear risk Waiting list controls have a risk of over-
estimating the benefit of an intervention.
However, all participants in thewaiting lists
were to receive the active intervention at
the end of the randomised phase (eligibility
to receive active intervention was not con-
ditional on severity or outcomes reported
during the study)
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Melin 1987
Methods 2-arm, non-blinded, multi-centre, parallel-group RCT, with a 6 weeks follow-up
Participants Location: Sweden, 1 site
Setting of recruitment and treatment: hearing clinic at a Swedish university hospital
Sample size:
• Number randomised: 39 (20 intervention, 19 control)
• Number completed: 39 (attrition 0%)
Participant (baseline) characteristics:
• Age: mean 72.7 years (SD 10.6)
• Gender: 13 male, 26 female
• Main diagnosis: hearing loss (PTA averaged across 0.5, 1.0, 2.0, 4.0 kHz) left =
40.5 dB HL (SD 11.9) right = 39.05 (SD 13.1)
• Other important effect modifiers: none
Inclusion criteria: hearing loss to a degree that hearing aids were needed, no prior
hearing aid experience, tinnitus duration for more than 6 months
Exclusion criteria: none noted
Interventions Intervention group (n = 20): hearing aids (manufacturer: Widex, Rexton, Oticon,
Siemens, Philips, Danavox), unilateral fits (95%) 6 weeks post-baseline. Fitting not
specified
Comparator group (n = 19): waiting list controls, no hearing aids up to 6 weeks post-
baseline
Use of additional interventions (common to both treatment arms): none up to 6
weeks post-baseline, then both groups had hearing aids
Outcomes Primary outcomes: Hearing Scaling (easy, fairly easy, fairly difficult, difficult), 6 weeks
post-fitting
Secondary outcomes: none specified
Reported outcomes: as for primary outcomes
Hearing Scaling assessment was not included in the analysis of listening abilities because
not all of the data required were available in the paper and were no longer available
Funding sources Bank of Sweden Tercentenary Foundation (grant No. 83/16) and grants from Stifrelsen,
Stockholm and Oticon Foundation, Copenhagen
Declarations of interest None noted
Notes 6 weeks after baseline, hearing aids were fitted to the control group and the study
continued to 10 weeks follow-up for each group
Hearing aids were provided at no cost.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Insufficient information was provided in
the paper.Quote: “To prevent bias, the ran-
dom allocations of the subjects were done
after their first interview according to a ran-
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Melin 1987 (Continued)
domisation plan”
However, contact with the authors revealed
randomisation was most likely done in
blocks of 10 (5 participants experimental
group, 5 participants control group) to re-
cruit groups of the same size
Allocation concealment (selection bias) Low risk Insufficient information was provided in
the paper.Quote: “To prevent bias, the ran-
dom allocations of the subjects were done
after their first interview according to a ran-
domisation plan”
However, contact with the authors revealed
that the allocation to group was concealed
by using pre-prepared opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Noblinding, therefore patients andperson-
nel were aware of the intervention. Possible
that the hearing aid group were treated dif-
ferently compared to the waiting list group
in other aspects
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding and outcomes were likely to
have been influenced by the lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No participant dropouts, but insufficient
reporting of whether all data points from
the hearing scale were completed by group.
Historic records not available
Selective reporting (reporting bias) Low risk Study protocol not available but the au-
thors indicated that nomeasures other than
the listening scaling task were included in
the study
Other bias Unclear risk Waiting list controls have a risk of overes-
timating the benefit of an intervention
However, all participants in thewaiting lists
were to receive the active intervention at
the end of the experimental phase (not con-
ditional on severity at the end of the study)
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Mulrow 1990
Methods 2-arm, non-blinded, single-centre, parallel-group RCT, with 16 weeks duration of treat-
ment and follow-up at 6 and 16 weeks
Participants Location: USA, 1 site
Setting of recruitment and treatment:US veterans undergoing hearing assessment tests
at the Audie L. Murphy Memorial Veterans Hospital and associated primary care clinics
Sample size:
• Number randomised: 194 (95 intervention, 99 control)
• Number completed: 188 (92 in intervention, 96 in comparison; attrition n = 6
(3.1%), due to death n = 5, moved outside the 100 mile limit n = 1)
Participant (baseline) characteristics:
• Age: hearing aid group 73 (± 7); control group 71 (± 5)
• Gender: hearing aid group 100% male, 0% female; control group 99% male, 1%
female
• Main diagnosis: hearing loss (hearing aid group PTA 1.0, 2.0, 4.0 kHz better ear:
53 (± 10) dB HL; control group PTA 1.0, 2.0, 4.0 kHz better ear: 51 (± 8) dB HL
• Other important effect modifiers: none
Inclusion criteria: PTA at 2 kHz better ear >= 40 dB HL in better hearing ear, over 64
years
Exclusion criteria: severely disabling comorbid disease, current hearing aid users, live
more than 100 miles from the clinic, existing hearing aid users
Interventions Intervention group (n = 95): hearing aids (manufacturer not specified), in-the-ear
(98%), unilateral fits (97%), typically to the worst hearing ear
Comparator group (n = 99): waiting list controls, no hearing aids
Use of additional interventions (common to both treatment arms): none
Outcomes Primary outcomes: none specified
Secondary outcomes: none specified
Reported outcomes: baseline and 16 weeks post-fitting. Hearing Handicap Inventory
for the Elderly, Quantified Denver Scale, Short Portable Mental Status Questionnaire,
Geriatric Depression Scale, Self Evaluation and Life Function. HHIE and QDS also
measured at 6 weeks. HHIE results at 16 weeks used in meta-analyses
Funding sources RobertWood Johnson Foundation, a Milbank Scholar Program Award and an American
College of Physicians’ Teaching and Research Scholar Award
Declarations of interest None noted
Notes Hearing aids provided at no cost
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Sequence generated using block randomi-
sation with a block size of 6 (3 x 2 treat-
ments)
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Mulrow 1990 (Continued)
Allocation concealment (selection bias) Low risk Use of blocked randomisation could have
created situations in which allocations at
the end of a block can be guessed. How-
ever, a block size of 6 (3 x 2 treatments)
would have created sufficient uncertainty.
Concealment was facilitated through use of
a remote telephone allocation service
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Noblinding, therefore patients andperson-
nel were aware of the intervention. Possible
that the hearing aid group were treated dif-
ferently compared to the waiting list group
in other aspects
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding, and outcomes were likely to
have been influenced by the lack of blind-
ing
Quote: “All scales were self-administered,
except the SPMSQ which was adminis-
tered by a trained interviewer”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcome data due to dropouts that
were even across treatment and control
groups and for which reasonswere reported
and unlikely to be related to the true out-
come
Selective reporting (reporting bias) Low risk No published study protocol. However, no
evidence to support the suggestion that the
published reports did not include all the ex-
pected outcomes including those that were
pre-specified
Other bias Unclear risk Waiting list controls have a risk of over-
estimating the benefit of an intervention.
However, all participants in the waiting list
group were to receive the active interven-
tion at the end (not conditional on severity
at the end of the study)
AD: Alzheimer’s disease
APHAB: Abbreviated Profile of Hearing Aid Benefit
CTC: clinical trial co-ordinator
dB: decibel
DSM-IV: Diagnostic and Statistical Manual of Mental Disorders - IV
HHIE: Hearing Handicap Inventory for the Elderly
HL: hearing level
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MMSE: Mini-Mental State Examination
NAL: National Acoustic Laboratories
NL1: non-linear, version 1
NL2: non-linear, version 2
NINCDS-ADRDA: National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and
Related Disorders Association
PTA: pure-tone average
QDS: Quantified Denver Scale of Communication
R: revised
RCT: randomised controlled trial
SD: standard deviation
SNHL: sensorineural hearing loss
SPMSQ: Short Portable Mental Status Questionnaire
WHO-DAS: World Health Organization Disability Assessment Schedule
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abrams 2002 ALLOCATION: not true randomisation, as patients were allocated by eligibility for VA funded hearing aids: those
eligible for funding through the VA received hearing aids; those not eligible for hearing aids acted as controls
Jerger 1992 ALLOCATION: non-randomised controlled trial
Lavie 2015 ALLOCATION: non-randomised controlled trial
Tolson 2002 ALLOCATION: randomised controlled trial
PARTICIPANTS: definition of hearing loss does not meet the inclusion criterion
Yueh 2001 ALLOCATION: not true randomisation, as patients were allocated by eligibility for VA funded hearing aids: those
eligible for funding through the VA received hearing aids; those not eligible for hearing aids acted as controls
VA: Veterans Association
Characteristics of ongoing studies [ordered by study ID]
NCT03002142
Trial name or title Auditory Rehabilitation and Cognition in Alzheimer Patients (RACO-MA)
Methods Randomised controlled trial, double-blind design
Participants Adults with Alzheimer’s disease and hearing loss
Interventions Hearing aids and placebo
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NCT03002142 (Continued)
Outcomes Alzheimer’s Disease Assessment Scale - cognitive scale (primary), pure-tone and speech audiometry, Mini-
Mental State Examination, Hearing Handicap Inventory for the Elderly (HHIE), Hearing Loss Impact Scale
in Adults (HLSiA), Quality of life - Alzheimer’s disease scale, Zarit scale for caregiver burden, Geriatric
Depression Scale, Trail Making Test for executive function, Wechsler Adult Intelligence Scale, Beauregard
test for speech comprehension, Glasgow Hearing Aid Benefit Profile (GHABP). Outcomes of interest to this
review are the HHIE, HLISiA and GHABP
Starting date December 2016
Contact information None supplied
Notes University Hospital, Tours, France
39Hearing aids for mild to moderate hearing loss in adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
Comparison 1. Hearing aids versus no/placebo hearing aids
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Hearing-specific health-related
quality of life
3 722 Mean Difference (IV, Random, 95% CI) -26.47 [-42.16, -10.
77]
1.1 Subgroup A (community
setting, male-female balance,
behind-the-ear hearing aids,
placebo control)
1 154 Mean Difference (IV, Random, 95% CI) -10.54 [-15.26, -5.
82]
1.2 Subgroup B (Veterans
Association setting, mostly
male, in-the-ear hearing aids,
waiting list control)
2 568 Mean Difference (IV, Random, 95% CI) -33.48 [-36.72, -30.
23]
2 Health-related quality of life 2 568 Std. Mean Difference (IV, Random, 95% CI) -0.38 [-0.55, -0.21]
2.1 WHO Disability
Assessment Schedule 2.0
(WHO-DAS II, range 0 to
100, lower is better)
1 380 Std. Mean Difference (IV, Random, 95% CI) -0.44 [-0.65, -0.24]
2.2 Self-evaluation of Life
Function (SELF, range 54 to
216, lower is better)
1 188 Std. Mean Difference (IV, Random, 95% CI) -0.26 [-0.55, 0.03]
3 Listening ability 2 534 Std. Mean Difference (IV, Random, 95% CI) -1.88 [-3.24, -0.52]
3.1 Profile of Hearing Aid
Performance (PHAP, range 0 to
1, lower is better)
1 154 Std. Mean Difference (IV, Random, 95% CI) -1.18 [-1.54, -0.81]
3.2 Abbreviated Profile of
Hearing Aid Benefit (APHAB,
range 0 to 100, lower is better)
1 380 Std. Mean Difference (IV, Random, 95% CI) -2.57 [-2.84, -2.30]
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Analysis 1.1. Comparison 1 Hearing aids versus no/placebo hearing aids, Outcome 1 Hearing-specific
health-related quality of life.
Review: Hearing aids for mild to moderate hearing loss in adults
Comparison: 1 Hearing aids versus no/placebo hearing aids
Outcome: 1 Hearing-specific health-related quality of life
Study or subgroup Hearing aids
No/placebo
hearing aids
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Subgroup A (community setting, male-female balance, behind-the-ear hearing aids, placebo control)
Humes 2017 104 13.46 (14.28) 50 24 (13.86) 33.5 % -10.54 [ -15.26, -5.82 ]
Subtotal (95% CI) 104 50 33.5 % -10.54 [ -15.26, -5.82 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.38 (P = 0.000012)
2 Subgroup B (Veterans Association setting, mostly male, in-the-ear hearing aids, waiting list control)
Mulrow 1990 92 14.7 (17.7) 96 51.2 (28) 32.5 % -36.50 [ -43.17, -29.83 ]
McArdle 2005 189 10.5 (11.49) 191 43.07 (22.12) 34.0 % -32.57 [ -36.11, -29.03 ]
Subtotal (95% CI) 281 287 66.5 % -33.48 [ -36.72, -30.23 ]
Heterogeneity: Tau2 = 0.31; Chi2 = 1.04, df = 1 (P = 0.31); I2 =4%
Test for overall effect: Z = 20.21 (P < 0.00001)
Total (95% CI) 385 337 100.0 % -26.47 [ -42.16, -10.77 ]
Heterogeneity: Tau2 = 185.49; Chi2 = 63.84, df = 2 (P<0.00001); I2 =97%
Test for overall effect: Z = 3.31 (P = 0.00095)
Test for subgroup differences: Chi2 = 61.57, df = 1 (P = 0.00), I2 =98%
-100 -50 0 50 100
Favours hearing aids Favours no hearing aids
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Analysis 1.2. Comparison 1 Hearing aids versus no/placebo hearing aids, Outcome 2 Health-related quality
of life.
Review: Hearing aids for mild to moderate hearing loss in adults
Comparison: 1 Hearing aids versus no/placebo hearing aids
Outcome: 2 Health-related quality of life
Study or subgroup Hearing aids No hearing aids
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 WHO Disability Assessment Schedule 2.0 (WHO-DAS II, range 0 to 100, lower is better)
McArdle 2005 189 12.7 (12.9) 191 19.16 (15.99) 65.6 % -0.44 [ -0.65, -0.24 ]
Subtotal (95% CI) 189 191 65.6 % -0.44 [ -0.65, -0.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.27 (P = 0.000020)
2 Self-evaluation of Life Function (SELF, range 54 to 216, lower is better)
Mulrow 1990 92 92 (18.2) 96 96.8 (18.8) 34.4 % -0.26 [ -0.55, 0.03 ]
Subtotal (95% CI) 92 96 34.4 % -0.26 [ -0.55, 0.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.76 (P = 0.078)
Total (95% CI) 281 287 100.0 % -0.38 [ -0.55, -0.21 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 1.06, df = 1 (P = 0.30); I2 =6%
Test for overall effect: Z = 4.31 (P = 0.000016)
Test for subgroup differences: Chi2 = 1.06, df = 1 (P = 0.30), I2 =6%
-1 -0.5 0 0.5 1
Favours hearing aids Favours no hearing aids
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Analysis 1.3. Comparison 1 Hearing aids versus no/placebo hearing aids, Outcome 3 Listening ability.
Review: Hearing aids for mild to moderate hearing loss in adults
Comparison: 1 Hearing aids versus no/placebo hearing aids
Outcome: 3 Listening ability
Study or subgroup Hearing aids No hearing aids
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Profile of Hearing Aid Performance (PHAP, range 0 to 1, lower is better)
Humes 2017 104 0.22 (0.12) 50 0.37 (0.14) 49.6 % -1.18 [ -1.54, -0.81 ]
Subtotal (95% CI) 104 50 49.6 % -1.18 [ -1.54, -0.81 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.36 (P < 0.00001)
2 Abbreviated Profile of Hearing Aid Benefit (APHAB, range 0 to 100, lower is better)
McArdle 2005 189 18.11 (9.81) 191 51.21 (15.3) 50.4 % -2.57 [ -2.84, -2.30 ]
Subtotal (95% CI) 189 191 50.4 % -2.57 [ -2.84, -2.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 18.49 (P < 0.00001)
Total (95% CI) 293 241 100.0 % -1.88 [ -3.24, -0.52 ]
Heterogeneity: Tau2 = 0.94; Chi2 = 36.12, df = 1 (P<0.00001); I2 =97%
Test for overall effect: Z = 2.70 (P = 0.0069)
Test for subgroup differences: Chi2 = 36.12, df = 1 (P = 0.00), I2 =97%
-4 -2 0 2 4
Favours hearing aids Favours no hearing aids
A P P E N D I C E S
Appendix 1. Search strategies
CRSO MEDLINE (Ovid) Embase (Ovid)
#1 MESH DESCRIPTOR Hearing Loss
EXPLODE ALL TREES
#2 MESH DESCRIPTOR Persons With
Hearing Impairments EXPLODE ALL
TREES
#3 (hearing near (loss or impair*)):TI,AB,
1 exp Hearing Loss/
2 exp Persons With Hearing Impairments/
3 (hearing adj3 (loss or impair*)).ab,ti.
4 ”deaf*“.ab,ti.
5 1 or 2 or 3 or 4
6 Hearing Aids/
1 exp hearing impairment/
2 (hearing adj3 (loss or impair*)).ti,ab.
3 ”deaf*“.ti,ab.
4 1 or 2 or 3
5 hearing aid/
6 (”hearing aid*“ or hearing-aid* or ”hear-
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(Continued)
KY
#4 deaf*:TI,AB,KY
#5 #1 OR #2 OR #3 OR #4
#6 MESH DESCRIPTOR Hearing Aids
#7 (”hearing aid*“ or hearing-aid* or ”hear-
ing device*“ or ”hearing instrument*“ or
”hearing system*“):TI,AB,KY
#8 (hearing near (loss or impair*) near (am-
plif* or aided or unaided or aid)):TI,AB,
KY
#9 #6 OR #7 OR #8
#10 #5 AND #9
7 (hearing adj3 (loss or impair*) adj6 (am-
plif* or aided or unaided or aid)).ab,ti
8 (”hearing aid*“ or hearing-aid* or ”hear-
ing device*“ or ”hearing instrument*“ or
”hearing system*“).ab,ti
9 6 or 7 or 8
10 5 and 9
ing device*“ or ”hearing instrument*“ or
”hearing system*“).ti,ab
7 (hearing adj3 (loss or impair*) adj6 (am-
plif* or aided or unaided or aid)).ti,ab
8 5 or 6 or 7
9 4 and 8
CINAHL LILACS Trial Registries
S9 S4 AND S8
S8 S5 OR S6 OR S7
S7TX (hearingn3 (loss or impair*) n6 (am-
plif* or aided or unaided))
S6 TX ”hearing aid*“ or hearing-aid* or
”hearing device*“ or ”hearing instrument*“
or ”hearing system*“
S5 (MH ”Hearing Aids“)
S4 S1 OR S2 OR S3
S3 TX deaf*
S2 TX hearing n3 (loss or impair*)
S1 (MH ”Hearing Disorders“) OR (MH
”Deafness“) OR (MH ”Hearing Loss, Par-
tial+“)
((((TW:hearing OR TW:Auditiva) AND
(TW:loss OR TW:impair* OR TW:perd*)
) OR TW:deaf*) AND (TW:amplif* or
TW:aided or TW:unaided or TW:aid))
OR TW:”hearing aid*“ or TW:hearing-
aid* or TW:”hearing device*” or TW:
”hearing instrument*“ or TW:”hearing sys-
tem*” OR TW:Audífonos OR TW:”Aux-
iliares de Audição”
ClinicalTrials.gov
“hearing aid” OR “hearing aids” OR (
(“hearing loss” OR “hearing impairment”)
AND (amplification OR aided OR aid OR
unaided))
OR
Intervention: “hearing aid” OR “hearing
aids” OR ((“hearing loss” OR “hearing im-
pairment”) AND (amplification OR aided
OR aid OR unaided))
ICTRP
hearing aid* or hearing-aid* or “hearing de-
vice*” or “hearing instrument*” or “hear-
ing system*”
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MF conceived the review question, selected which studies to review, extracted data, assessed study quality, wrote the protocol and
review, and co-ordinated comments from the authors and reviewers.
PK extracted data, assessed study quality, conducted the data analyses, and contributed substantially to the writing of the protocol and
review.
LY provided methodological advice on the protocol and the review.
MEJ provided statistical advice and conducted an independent verification of the data analyses.
FB joined as a co-author for the full review, selected which studies to include and provided feedback on the review.
DH selected which studies to include, assessed study quality, and provided guidance and critical comment on the draft protocol and
review.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The Types of participants section in the protocol was: “Adults (≥ 18 years old) with mild or moderate hearing loss, as defined by pure-
tone thresholds in the better-hearing ear averaged across four frequencies (0.5 kHz, 1.0 kHz, 2.0 kHz and 4.0 kHz) of 26 to 40 dB
HL (mild hearing loss) and 41 to 60 dB HL (moderate hearing loss). In the absence of confirmation that all participants in a study
met these criteria (i.e. where participant-level data were not reported or could not be obtained), we will include studies where the
reported participant characteristics for the mean four-frequency average as described above. If a mean frequency average is offered for
a combination of frequencies other than 0.5 kHz, 1.0 kHz, 2.0kHz and 4.0 kHz, we will use studies where the reported value falls
between 26 to 40 dB HL (mild hearing loss) or 41 to 60 dB HL (moderate hearing loss). If only qualitative descriptions of mild and
moderate hearing loss are given with no supporting audiometric data, we will include such studies but will not include them in the
meta-analysis” (Ferguson 2015).
We revised the Types of participants section because there was concern about introducing a potential bias in the selection of studies
such that those studies that were reported in less detail (e.g. group mean hearing threshold data or qualitative descriptions) were more
likely to be included than those that either reported in more detail or provided us with participant-level data. To minimise the risk of
bias from the revision of the protocol, the revised definition for Types of participants and the final decisions about which studies met
the inclusion criteria were subjected to an independent review by an external expert committee to ensure the decisions were appropriate
for the review question.
The protocol stated that MF and FB would extract the data, but instead this was completed by MF and PK. The protocol did not state
what would happen in the event of a disagreement on a risk of bias judgement between MF and PK. Where this occurred, DH was
charged with making a final judgement. The protocol stated that MF would review the ’Summary of findings’ table, but in addition
LYC (who was not an author on the review protocol) also reviewed the ’Summary of findings’ table.
The protocol stated in Measures of treatment effect that we would use the standardised mean difference at the trial endpoint. We
instead used the mean difference for the hearing-specific health-related quality of life outcome at the trial endpoint as these data were
collected using the same instrument (HHIE) across all studies that were included in the meta-analysis.
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Some of the pre-specified subgroup and funnel plot analyses were not performed as the data were not available or were too limited.
We performed unplanned subgroup analyses for the hearing-specific quality of life and listening ability outcomes due to the numerous
participant and methodological differences between the Veterans Association studies and the other study included in the analyses
(Humes 2017).
We made a minor adjustment to the wording of the review Objectives, changing ’effectiveness’ to ’effects’ to capture our interest in
both positive and negative outcomes.
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